7639-68-1

Basic information

• Product Name: 4,4,4-TRIFLUORO-1-(1-NAPHTHYL)BUTANE-1,3-DIONE
• Synonyms: ART-CHEM-BB B007355;4,4,4-TRIFLUORO-1-(1-NAPHTHYL)BUTANE-1,3-DIONE;4,4,4-TRIFLUORO-1-NAPHTHALEN-1-YL-BUTANE-1,3-DIONE;AKOS B007355;4,4,4-Trifluoro-1-(1-naphthalenyl)-1,3-butanedione
• CAS NO: 7639-68-1
• Molecular Formula: C₁₄H₉F₃O₂
• Molecular Weight: 266.22
• Mol File: 7639-68-1.mol
• Article Data: 3

Chemical Properties

• Melting Point: 45-46 °C
• Boiling Point: 350.7±37.0 °C(Predicted)
• Appearance: /
• Density: 1.320±0.06 g/cm3(Predicted)
• PKA: 7.70±0.50(Predicted)
• CAS DataBase Reference: 4,4,4-TRIFLUORO-1-(1-NAPHTHYL)BUTANE-1,3-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4,4-TRIFLUORO-1-(1-NAPHTHYL)BUTANE-1,3-DIONE(7639-68-1)
• EPA Substance Registry System: 4,4,4-TRIFLUORO-1-(1-NAPHTHYL)BUTANE-1,3-DIONE(7639-68-1)

Safety Data

• Hazardous Substances Data: 7639-68-1(Hazardous Substances Data)

Usage

General Description

4,4,4-trifluoro-1-(1-naphthyl)butane-1,3-dione is a chemical compound with the molecular formula C15H10F3O2. It is a yellow solid that is primarily used in organic synthesis and as a reagent in various chemical reactions. 4,4,4-TRIFLUORO-1-(1-NAPHTHYL)BUTANE-1,3-DIONE is characterized by its unique structure, with a butanedione core attached to a 1-naphthyl group and three fluorine atoms. It is used in the production of pharmaceuticals, agrochemicals, and materials science applications due to its ability to form complex molecular structures and functional groups. Additionally, it is also used as a fluorescent probe in biochemical and biomedical research due to its ability to emit fluorescence when excited by ultraviolet light.

Upstream product

• 941-98-0 1'-naphthacetophenone 
• 383-63-1 ethyl trifluoroacetate, 

Downstream Products

• 1177469-53-2 4-(5-naphthalen-1-yl-3-trifluoromethyl-pyrazol-1-yl)-phenylamine 
• 1252678-95-7 5-Naphthalen-1-yl-1-(4-nitro-phenyl)-3-trifluoromethyl-1H-pyrazole 
• 1177469-45-2 4-(5-naphthalen-1-yl-3-trifluoromethyl-pyrazol-1-yl)-benzenesulfonamide 

Relevant articles and documents

Bright Yb3+ complexes for efficient pure near-infrared OLEDs

A series of neutral Yb3+ and Gd3+ complexes with isomeric 4,4,4-trifluoro-1-(naphthalenyl)butane-1,3-diones and 1,10-phenanthroline as an ancillary ligand were synthesized and characterized by a full range of analytical methods, including elemental analysis, FTIR and NMR spectroscopy, single crystal X-ray analysis, cyclic voltammetry (CVA) and thermal analysis (TG/DTA). Moreover, the unexpected formation of a mixed diketonate-carboxylate Yb3+ complex [Yb(2-Naph)2(CF3COO)(phen)(H2O)] from [Yb(2-Naph)3(phen)] in solution was observed. The photoluminescence quantum yield (PLQY) for complex [Yb(2-Naph)3(phen)] in the near infra-red region (one band with a peak at 980 nm) was about 3,2%. This value is close to the highest one reported for 1,3-diketonate complexes of Yb3+ ion to date. The energy transfer process is discussed in details, based on the results of TD-DFT calculations and experimental photophysical measurements. These complexes were successfully used as emitters in multilayer OLEDs. The electroluminescence quantum efficiency corresponding to the sole band at 980 nm reached 0.042% with a maximum irradiance of 11 μW/cm2 at 8.5 V for [Yb(2-Naph)3(phen)] based device, which is unusually high for such type of emitters.

Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA.